High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a
standard of care for selected patients with refractory/relapsed Hodgkin's lymphoma (HL) or …

Over the last few years, there have been many changes in the management of patients with
follicular lymphoma, resulting in improvements in progression-free survival and quality of …

Background Bendamustine is a potent chemotherapy agent increasingly used to treat
indolent non-Hodgkin lymphoma (iNHL). While effective, it causes significant T-cell …

Background Rituximab plus bendamustine (R‐B) has been demonstrated to improve
outcomes and reduce toxicity compared with rituximab, cyclophosphamide, doxorubicin, and …

Chimeric antigen receptor (CAR) T cells are an established treatment for B cell non-Hodgkin
lymphomas (B-NHL). With the remarkable success in improving survival, understanding the …

Hairy cell leukemia variant (HCLv) is a chronic lymphoproliferative disorder classified as a
provisional entity in the 2016 WHO Classification of Lymphoid Tumors. HCLv is …

Bendamustine and rituximab (BR) is a preferred first‐line therapy for indolent non‐Hodgkin's
lymphoma (iNHL) and mantle cell lymphoma (MCL); however, few reports on BR …

Bendamustine is used in combination with rituximab (BR) to treat indolent non‐Hodgkin
lymphomas (iNHL) and mantle cell lymphoma (MCL). The variability in treatment efficacy …

Aim: Characterize follicular lymphoma (FL) treatment patterns among elderly patients using
a dataset with longer follow-up time. Materials & methods: Using the linked Surveillance …

Marginal zone lymphoma (MZL) is an uncommon indolent lymphoma classified into
subtypes based on primary site of involvement: splenic, nodal and extranodal. MZLs' relative …